Bionano Genomics reported a 3% year‑over‑year decline in Q4 revenue and narrowed its net loss substantially versus the prior year, citing steady R&D and reduced SG&A. The company sold fewer flow cells in the quarter but grew installed optical genome mapping (OGM) systems to 387 units and guided modest revenue for FY2026. Importantly, Bionano noted a 47% increase in the Centers for Medicare & Medicaid Services (CMS) clinical lab fee schedule payment determination for the Category I CPT code covering OGM for hematologic malignancies, a change that could materially improve clinical reimbursement dynamics for OGM adoption in oncology diagnostics.